KNOXVILLE, TENNESSEE, UNITED STATES, October 3, 2021 /EINPresswire.com/ – On September 27, Nima Tamaddoni, CEO of T&T Scientific, announces its revolutionary manufacturing platform for therapeutic genetic nanomedicine and RNA (mRNA) vaccines such as COVID-19 vaccines.
T&T Scientific Managing Director Dr Nima Tamaddoni made the announcement live. He said: “It is a real honor and pleasure to push the NanoSizer FLOW GMP to the finish line and launch it. We launched this platform to help millions of people get gene therapies and life-saving vaccines as quickly as possible, with the best quality and at the lowest possible cost. Whether you are a small business or a large pharmaceutical manufacturer, or a formulation company, this platform provides a reliable, low cost, high quality, high throughput solution in a very high operating range (100ml-500 L +) for the cGMP manufacture of nanomedicine therapies and vaccines. We believe this is truly and precisely the best nanomedicine manufacturing technology on the market. The T&T Scientific team is excited to help save lives by preventing and curing disease through new gene therapies and vaccines. and precisely adding value to the market to help the world access the prevention and treatment essential to save lives. r team and everyone involved in this technology that takes a lot of time and care to get to this point. “.
Some of the obvious competitive advantages can be listed below:
• No strings attached: customers and customers pay no license fees or royalties for the purchase
• Scalable in a wide range: it covers large-scale processing with the smallest footprint from 100 mL to 500 L + (continuous and batch modes)
• Low cost: significantly lower cost
• High quality: low PDI and high encapsulation efficiency (EE%)
• Quality control options: pressure and flow measurement
• Small footprint and worktop
• Compatible with tangential flow filtration (TFF) and sterile filtration after treatment
Alex Aust, MS, MBA, Director of Business Development at T&T Scientific, then gave a live demonstration of the technology with LNP mRNA production, which can be seen at: https://www.youtube.com/watch?v=XgPC-95Z24U
T&T Scientific’s future effort is to complement this technology with full downstream filtration, including tangential flow filtration and downstream sterile filtration in filling and finishing technologies, all in a closed system. T&T also offers contract development and manufacturing services, from preclinical to commercial manufacturing.
It is important to note that T&T technology comes with full quality validation and qualification packages for GMP operation, and no royalty or license is required for customers to pay at any time. Once the unit is purchased, it will be yours. This is a clear and competitive advantage in helping the world use these systems anywhere from small to large pharmaceutical labs and manufacturing lines to site fields in Africa. This system can be set up, qualified and validated for the indispensable manufacture of therapeutic products and life-saving vaccines.
Nima Tamaddoni, Ph.D.,
T&T Scientific Corp.